Literature DB >> 26587331

Functional expression of CD137 (4-1BB) on T helper follicular cells.

Carlos Alfaro1, Jose I Echeveste2, Maria E Rodriguez-Ruiz1, Jose L Solorzano2, Jose L Perez-Gracia3, Miguel A Idoate2, Jose M Lopez-Picazo3, Alfonso R Sanchez-Paulete4, Sara Labiano4, Ana Rouzaut4, Carmen Oñate1, Angela Aznar4, Maria D Lozano2, Ignacio Melero1.   

Abstract

CD137 (4-1BB) is a surface protein initially discovered to mark activated T lymphocytes. However, its broader expression pattern also encompasses activated NK cells, B cells and myeloid cells, including mature dendritic cells. In this study, we have immunostained for CD137 on paraffin-embedded lymphoid tissues including tonsils, lymph nodes, ectopic tertiary lymphoid tissue in Hashimoto thyroiditis and cancer. Surprisingly, immunostaining mainly decorated intrafollicular lymphocytes in the tissues analyzed, with only scattered staining in interfollicular areas. Moreover, pathologic lymphoid follicles in follicular lymphoma and tertiary lymphoid tissue associated with non-small cell lung cancer showed a similar pattern of immunostaining. Multispectral fluorescence cytometry demonstrated that CD137 expression was restricted to CD4+ CXCR5+ follicular T helper lymphocytes (TFH cells) in tonsils and lymph nodes. Short-term culture of lymph node cell suspensions in the presence of either an agonistic anti-CD137 monoclonal antibody (mAb) or CD137-ligand stimulated the functional upregulation of TFH cells in 3 out of 6 cases, as indicated by CD40L surface expression and cytokine production. As a consequence, immunostimulatory monoclonal antibodies targeting CD137 (such as urelumab and PF-05082566) should be expected to primarily act on this lymphocyte subset, thus modifying ongoing humoral immune responses in patients with autoimmune disease and cancer.

Entities:  

Keywords:  CD137 (4-1BB)v; T helper follicular cells; lymphoid follicle; tertiary lymphoid tissue

Year:  2015        PMID: 26587331      PMCID: PMC4635945          DOI: 10.1080/2162402X.2015.1054597

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  30 in total

Review 1.  T follicular helper cell differentiation, function, and roles in disease.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Authors:  Hye J Kim; Jong S Lee; Jung D Kim; Hee J Cha; Ahra Kim; Sun K Lee; Sang C Lee; Byoung S Kwon; Robert S Mittler; Hong R Cho; Byungsuk Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 3.  The good, the bad and the ugly - TFH cells in human health and disease.

Authors:  Stuart G Tangye; Cindy S Ma; Robert Brink; Elissa K Deenick
Journal:  Nat Rev Immunol       Date:  2013-05-17       Impact factor: 53.106

4.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Authors:  Ash A Alizadeh; Andrew J Gentles; Alvaro J Alencar; Chih Long Liu; Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Shuchun Zhao; Yasodha Natkunam; Ranjana H Advani; Randy D Gascoyne; Javier Briones; Robert J Tibshirani; June H Myklebust; Sylvia K Plevritis; Izidore S Lossos; Ronald Levy
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

5.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

6.  Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease.

Authors:  Yonglian Sun; Helen M Chen; Sumit K Subudhi; Jonathan Chen; Rima Koka; Lieping Chen; Yang-Xin Fu
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor.

Authors:  Hajime Nishimoto; Seung-Woo Lee; Hong Hong; Karen G Potter; Mari Maeda-Yamamoto; Tatsuya Kinoshita; Yuko Kawakami; Robert S Mittler; Byoung S Kwon; Carl F Ware; Michael Croft; Toshiaki Kawakami
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

8.  Molecular and biological characterization of human 4-1BB and its ligand.

Authors:  M R Alderson; C A Smith; T W Tough; T Davis-Smith; R J Armitage; B Falk; E Roux; E Baker; G R Sutherland; W S Din
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

Review 9.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.

Authors:  Ivan Martinez-Forero; Arantza Azpilikueta; Elixabet Bolaños-Mateo; Estanislao Nistal-Villan; Asis Palazon; Alvaro Teijeira; Gema Perez-Chacon; Aizea Morales-Kastresana; Oihana Murillo; Maria Jure-Kunkel; Juan M Zapata; Ignacio Melero
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more
  8 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

2.  Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Authors:  Maria C Ochoa; Elisabeth Perez-Ruiz; Luna Minute; Carmen Oñate; Guiomar Perez; Inmaculada Rodriguez; Aintzane Zabaleta; Diego Alignani; Myriam Fernandez-Sendin; Ascension Lopez; Aura Muntasell; Miguel F Sanmamed; Bruno Paiva; Miguel Lopez-Botet; Pedro Berraondo; Ignacio Melero
Journal:  Oncoimmunology       Date:  2019-04-13       Impact factor: 8.110

Review 3.  CD137, an attractive candidate for the immunotherapy of lung cancer.

Authors:  Lingyun Ye; Keyi Jia; Lei Wang; Wei Li; Bin Chen; Yu Liu; Hao Wang; Sha Zhao; Yayi He; Caicun Zhou
Journal:  Cancer Sci       Date:  2020-04-03       Impact factor: 6.716

Review 4.  Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.

Authors:  Christophe Pedros; Amnon Altman; Kok-Fai Kong
Journal:  Front Immunol       Date:  2018-10-22       Impact factor: 7.561

5.  A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Authors:  Marta Compte; Seandean Lykke Harwood; Ines G Muñoz; Rocio Navarro; Manuela Zonca; Gema Perez-Chacon; Ainhoa Erce-Llamazares; Nekane Merino; Antonio Tapia-Galisteo; Angel M Cuesta; Kasper Mikkelsen; Eduardo Caleiras; Natalia Nuñez-Prado; M Angela Aznar; Simon Lykkemark; Jorge Martínez-Torrecuadrada; Ignacio Melero; Francisco J Blanco; Jorge Bernardino de la Serna; Juan M Zapata; Laura Sanz; Luis Alvarez-Vallina
Journal:  Nat Commun       Date:  2018-11-15       Impact factor: 14.919

6.  Destroy, what destroys you.

Authors:  Khang Luu; Emily Nickles; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2019-11-03       Impact factor: 8.110

7.  Engineered off-the-shelf therapeutic T cells resist host immune rejection.

Authors:  Feiyan Mo; Norihiro Watanabe; Mary K McKenna; M John Hicks; Madhuwanti Srinivasan; Diogo Gomes-Silva; Erden Atilla; Tyler Smith; Pinar Ataca Atilla; Royce Ma; David Quach; Helen E Heslop; Malcolm K Brenner; Maksim Mamonkin
Journal:  Nat Biotechnol       Date:  2020-07-13       Impact factor: 54.908

8.  The influence of HK2 blood group antigen on human B cell activation for ABOi-KT conditions.

Authors:  Jingsong Cao; Luogen Liu; Yunsheng Zhang; Jianhua Xiao; Yi Wang
Journal:  BMC Immunol       Date:  2017-12-16       Impact factor: 3.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.